Layoffs
In addition, the company’s chief scientific officer, Seth Ettenberg, has resigned.
The changes are designed to extend the company’s cash runway to the end of 2021.
Bayer is moving closer to a $10 billion settlement over the Roundup lawsuits and the company is in the midst of restructuring.
It was a busy week for biotech quarterly and annual reports. Here’s a look at some of the top stories including Bristol-Myers Squibb, AbbVie, GSK, Merck and more.
One day after GlaxoSmithKline began to outline some of the broad strokes of splitting the company into two separate entities, more details are coming into place – particularly staffing concerns over the integration of the company’s vaccine business into its pharma operations.
The layoffs are in departments across the company that aren’t central to its consumer testing and therapeutics business.
As is often the case at the beginning and end of the year, a number of companies announced layoffs. Other news is related to lawsuits and an overall positive story about cancer death rates. Here’s a look.
Veritas Genetics was offering whole-genome sequencing for about $600, going head-to-head with companies like 23andMe and Ancestry.com. Earlier this week there were reports the company laid off 50 staffers and now they’ve announced they are ending operations in the U.S.
Most of the jobs are field-based positions across the U.S., although some will be in Thousand Oaks, California at the company’s headquarters.
Three years after Novartis opened a $1 billion research & development facility in Shanghai, the company is shifting the focus of the site from drug discovery to commercial development.
PRESS RELEASES
